natgillin/translations-raw huggingface dataset:
itraconazole), macrolide antibiotics (such as josamycin, clarithromycin, telithromycin or erythromycin given orally), medicines to treat HIV infections (such as nelfinavir, ritonavir) or nefazodone (medicine to treat depression) or diltiazem, verapamil (used for high blood pressure or angina pectoris); - if you are a woman able to have children and not using reliable contraception; - if you are pregnant or trying to become pregnant; - if you are breast-feeding. 
- če že jemljete zdravila proti glivičnim okužbam (na primer ketokonazol, itrakonazol), makrolidne antibiotike (na primer josamicin, klaritromicin, telitromicin ali eritromicin peroralno), zdravila proti okužbam z virusom HIV (na primer nelfinavir, ritonavir) ali nefazodon (zdravilo proti depresiji) ali diltiazem, verapamil (uporabljata se za zniževanje krvnega tlaka oz. zdravljenje angine pektoris);
Corlentor 5 mg: one film-coated tablet contains 5 mg ivabradine (equivalent to 5.390 mg ivabradine as hydrochloride). 
Corlentor 5 mg: ena filmsko obložena tableta vsebuje 5 mg ivabradina (kar ustreza 5,390 mg ivabradinijevega klorida).
- This medicine has been prescribed for you. 
Zdravilo je bilo predpisano vam osebno in ga ne smete dajati drugim.
Furthermore as elevated heart rate adversely affects the heart functioning and vital prognosis in patients with chronic heart failure, the specific heart rate lowering action of ivabradine helps to improve the heart functioning and vital prognosis in these patients. 
Specifičen učinek ivabradina na znižanje hitrosti srčnega utripa pomaga izboljšati delovanje srca ter življenjsko prognozo pri teh bolnikih.
Ivabradine is approximately 70% plasma protein bound and the volume of distribution at steady-state is close to 100 l in patients. 
Ivabradin se veže na beljakovine v plazmi v približno 70 % in volumen porazdelitve v stanju dinamičnega ravnovesja pri bolnikih znaša blizu 100 l. Največja koncentracija v plazmi po kroničnem jemanju priporočenega odmerka 5 mg dvakrat na dan je 22 ng/ml (koeficient variacije = 29 %).
Constipation Diarrhoea Abdominal pain* 
Bolezni prebavil občasni slabost zaprtje diareja bolečina v trebuhu*
- Hepatic impairment: in patients with mild hepatic impairment (Child Pugh score up to 7) unbound AUC of ivabradine and the main active metabolite were about 20% higher than in subjects with normal hepatic function. 
7) je nevezana površina pod krivuljo (AUC) ivabradina in poglavitnega aktivnega presnovka za približno 20 % večja, kot pri preiskovancih z normalnim delovanjem jeter.
Caution should be exercised when using ivabradine in patients with moderate hepatic impairment. 
Pri predpisovanju ivabradina bolnikom z zmerno jetrno okvaro morate biti previdni.
- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 - Resting heart rate below 70 beats per minute prior to treatment - Cardiogenic shock - Acute myocardial infarction - Severe hypotension (< 90/50 mmHg) - Severe hepatic insufficiency - Sick sinus syndrome - Sino-atrial block - Unstable or acute heart failure - Pacemaker dependent (heart rate imposed exclusively by the pacemaker) - Unstable angina - AV-block of 3rd degree - Combination with strong cytochrome P450 3A4 inhibitors such as azole antifungals 
srčna frekvenca med mirovanjem pod 70 utripov na minuto pred zdravljenjem kardiogeni šok akutni miokardni infarkt huda hipotenzija (< 90/50 mm Hg) hudo jetrno popuščanje sindrom bolnega sinusnega vozla sinoatrijski blok nestabilno ali akutno srčno popuščanje odvisnost od srčnega spodbujevalnika (srčna frekvenca, ki jo narekuje izključno srčni spodbujevalnik) nestabilna angina pektoris atrioventrikularni blok 3. stopnje kombinacija z močnimi zaviralci citokroma P450 3A4, kot so azolski antimikotiki (ketokonazol, itrakonazol), makrolidni antibiotiki (klaritromicin, eritromicin peroralno, josamicin, telitromicin), zaviralci proteaze virusa HIV (nelfinavir, ritonavir) in nefazodon (glejte poglavji 4.5 in 5.2) kombinacija z verapamilom ali diltiazemom, zmernima zaviralcema citokroma P450 3A4, ki imata lastnosti zniževanja srčne frekvence (glejte poglavje 4.5)
After two weeks of treatment, the dose can be increased to 7.5 mg twice daily if resting heart rate is persistently above 60 bpm or decreased to 2.5 mg twice daily (one half 5 mg tablet twice daily) if resting heart rate is persistently below 50 bpm or in case of symptoms related to bradycardia such as dizziness, fatigue or hypotension. 
utripov na minuto, ali zmanjšate na 2,5 mg dvakrat na dan (eno polovico 5-mg tablete dvakrat na dan), če je srčna frekvenca med mirovanjem vztrajno pod 50 utripov na minuto ali se pojavijo simptomi, povezani z bradikardijo, kot so omotica, utrujenost ali hipotenzija.
It is recommended that the decision to initiate or titrate treatment takes place with the availability of serial heart rate measurements, ECG or ambulatory 24-hour monitoring. 
Simptomatsko zdravljenje kronične stabilne angine pektoris Priporočljivo je, da se o uvedbi zdravljenja oz. povečanju odmerka odločate v skladu z razpoložljivimi serijskimi meritvami srčne frekvence, EKG oz. 24-urnim ambulantnim spremljanjem.
AV 1st degree block (ECG prolonged PQ interval) 
(EKG), ki se imenuje 'podaljšan interval QT';
- Non cardiovascular QT prolonging medicinal products (e.g. pimozide, ziprasidone, sertindole, 
ibutilid, amiodaron) - nesrčno-žilna zdravila, ki podaljšujejo interval QT (na primer pimozid, ziprazidon, sertindol,
Ivabradine has low affinity for CYP3A4, shows no clinically relevant CYP3A4 induction or inhibition and is therefore unlikely to modify CYP3A4 substrate metabolism or plasma concentrations. 
Ivabradin ima majhno afiniteto za citokrom P450 3A4, ki ga ne spodbuja ali zavira klinično pomembno,
What Corlentor looks like and contents of the pack Corlentor 5 mg tablets are salmon-coloured, oblong film-coated tablets scored on both sides, engraved with “5” on one face and on the other. 
Tablete zdravila Corlentor 5 mg so lososove barve, podolgovate in filmsko obložene, z zarezo na obeh straneh in vrezano oznako “5” na eni ter na drugi strani.
Ivabradine is metabolised by CYP3A4 only and it is a very weak inhibitor of this cytochrome. 
Ivabradin se presnavlja samo preko citokroma P450 3A4 in je njegov zelo blag zaviralec.
See package leaflet for the other excipients. 
Za ostale pomožne snovi glejte navodilo za uporabo.
Treatment of chronic heart failure Ivabradine is indicated in chronic heart failure NYHA II to IV class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ≥ 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated. 
do IV. razreda po funkcijski razvrstitvi Newyorškega društva za srce (NYHA) s sistolično disfunkcijo pri bolnikih v sinusnem ritmu, pri katerih je srčna frekvenca ≥ 75 utripov na minuto, v kombinaciji s standardno terapijo, vključno z zdravljenjem z antagonistom adrenergičnih receptorjev beta oziroma tudi ko je zdravljenje z antagonistom adrenergičnih receptorjev beta kontraindicirano ali ga bolnik ne prenaša dobro (glejte poglavje 5.1).
Ivabradine is indicated : - in adults unable to tolerate or with a contra-indication to the use of beta-blockers - or in combination with beta-blockers in patients inadequately controlled with an optimal beta blocker dose. 
Ivabradin je indiciran: - pri odraslih, pri katerih so antagonisti adrenergičnih receptorjev beta kontraindicirani ali jih ne prenašajo,
Ivabradine was shown not to influence the metabolism and plasma concentrations of other CYP3A4 substrates (mild, moderate and strong inhibitors). 
Dokazali so, da ivabradin ne vpliva na presnovo drugih substratov citokroma P450 3A4 in njihove koncentracije v plazmi
D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT 
D. POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN
Ivabradine should therefore be used with precaution in this population. 
Pri predpisovanju ivabradina tovrstnim bolnikom morate biti torej previdni.
One film-coated tablet contains 7.5 mg ivabradine (equivalent to 8.085 mg ivabradine as hydrochloride). 
Ena filmsko obložena tableta vsebuje 7,5 mg ivabradina (kar ustreza 8,085 mg ivabradinijevega klorida).
One film-coated tablet contains 5 mg ivabradine (equivalent to 5.390 mg ivabradine as hydrochloride). 
Ena filmsko obložena tableta vsebuje 5 mg ivabradina (kar ustreza 5,390 mg ivabradinijevega klorida).
Use in patients with congenital QT syndrome or treated with QT prolonging medicinal products The use of ivabradine in patients with congenital QT syndrome or treated with QT prolonging medicinal products should be avoided (see section 4.5). 
Uporaba pri bolnikih, ki imajo prirojeni sindrom podaljšanega intervala QT ali jemljejo zdravila, ki ga podaljšujejo
Headache, generally during the first month of treatment 
Bolezni živčevja pogosti glavobol, večinoma v prvem mesecu zdravljenja omotica, možno zaradi bradikardije občasni*
Corlentor (ivabradine) is a heart medicine used to treat: - Symptomatic stable angina pectoris (which causes chest pain) in adult patients whose heart rate is over or equal to 70 beats per minute. 
Kaj je zdravilo Corlentor in za kaj ga uporabljamo Corlentor (ivabradin) je zdravilo za srce, namenjeno za zdravljenje: simptomatske stabilne angine pektoris (bolezen, ki povzroča bolečine v prsih) pri odraslih bolnikih,
Talk to your doctor or pharmacist before taking Corlentor - if you suffer from heart rhythm disorders (such as irregular heartbeat, palpitation, increase in chest pain) or sustained atrial fibrillation (a type of irregular heartbeat), or an abnormality of electrocardiogram (ECG) called ‘long QT syndrome', - if you have symptoms such as tiredness, dizziness or shortness of breath (this could mean that your heart is slowing down too much), - if you suffer from symptoms of atrial fibrillation (pulse rate at rest unusually high (over 110 beats per minute) or irregular, without any apparent reason, making it difficult to measure), - if you have had a recent stroke (cerebral attack), - if you suffer from mild to moderate low blood pressure, - if you suffer from uncontrolled blood pressure, especially after a change in your antihypertensive treatment, - if you suffer from severe heart failure or heart failure with abnormality of ECG called ‘bundle branch block', - if you suffer from chronic eye retinal disease, - if you suffer from moderate liver problems, - if you suffer from severe renal problems. 
- če opažate simptome, kot so utrujenost, vrtoglavost ali zasoplost (to bi lahko pomenilo, da se vaše srce preveč upočasnjuje); - če imate simptome atrijske fibrilacije (nenavadno visok srčni utrip v mirovanju (nad 110 utripov na minuto) ali brez posebnega vzroka nereden srčni utrip, ki ga je težko izmeriti); - če ste nedavno imeli možgansko kap (možganski napad); - če imate blago do zmerno znižan krvni tlak;
The metabolism of this active metabolite also involves CYP3A4. 
Presnova aktivnega presnovka prav tako zajema citokrom P450 3A4.
NAME OF THE MEDICINAL PRODUCT Corlentor 5 mg film-coated tablets ivabradine 
Corlentor 5 mg filmsko obložene tablete ivabradin
Precautions for use 
B. NAVODILO ZA UPORABO
Other concomitant use 
Drugo sočasno jemanje
Corlentor 5 mg film-coated tablets Corlentor 7.5 mg film-coated tablets ivabradine 
Corlentor 7,5 mg filmsko obložene tablete ivabradin
In the SHIFT trial more patients experienced episodes of increased blood pressure while treated with ivabradine (7.1%) compared to patients treated with placebo (6.1%). 
(7,1 %) v primerjavi z bolniki, ki so prejemali placebo (6,1 %).
Angioedema Rash 
eritem srbenje urtikarija
Malaise, possibly related to bradycardia 
občutek slabosti, možno zaradi bradikardije
C OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION 
B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE C. DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET Z
Salmon-coloured, oblong, film-coated tablet scored on both sides, engraved with “5” on one face and on the other face. 
Podolgovata, filmsko obložena tableta lososove barve z zarezo na obeh straneh in vrezano oznako “5” na eni ter na drugi strani.
In the subgroup of patients with HR ≥ 75 bpm (n=4150), a greater reduction was observed in the primary composite endpoint of 24 % (hazard ratio: 0.76, 95%CI [0.68;0.85] - p<0.0001) and for other secondary endpoints, including all cause death (hazard ratio: 0.83, 95%CI [0.72;0.96] - p=0.0109) and CV death (hazard ratio: 0.83, 95%CI [0.71;0.97] - p=0.0166). 
(razmerje tveganja: 0,83, 95 % interval zaupanja [0,72; 0,96] - p=0,0109) in srčno-žilno umrljivostjo (razmerje tveganja: 0,83, 95 % interval zaupanja [0,71; 0,97] - p=0,0166).
In a 889-patients randomised placebo-controlled study, ivabradine given on top of atenolol 50 mg o.d. showed additional efficacy on all ETT parameters at the trough of drug activity (12 hours after oral intake). 
V randomizirani, s placebom nadzorovani študiji pri 889 bolnikih, ki so ivabradin jemali poleg atenolola
josamycin, telithromycin), HIV protease inhibitors (nelfinavir, ritonavir) and nefazodone (see sections 4.5 and 5.2) - Combination with verapamil or diltiazem which are moderate CYP3A4 inhibitors with heart rate reducing properties (see section 4.5) - Pregnancy, lactation and women of child-bearing potential not using appropriate contraceptive measures (see section 4.6) 
hudo jetrno popuščanje sindrom bolnega sinusnega vozla sinoatrijski blok nestabilno ali akutno srčno popuščanje odvisnost od srčnega spodbujevalnika (srčna frekvenca, ki jo narekuje izključno srčni spodbujevalnik) nestabilna angina pektoris atrioventrikularni blok 3. stopnje kombinacija z močnimi zaviralci citokroma P450 3A4, kot so azolski antimikotiki (ketokonazol, itrakonazol), makrolidni antibiotiki (klaritromicin, eritromicin peroralno, josamicin, telitromicin), zaviralci proteaze virusa HIV (nelfinavir, ritonavir) in nefazodon (glejte poglavji 4.5 in 5.2) kombinacija z verapamilom ali diltiazemom, zmernima zaviralcema citokroma P450 3A4, ki imata lastnosti zniževanja srčne frekvence (glejte poglavje 4.5)
Salmon-coloured, triangular, film-coated tablet engraved with “7.5” on one face and on the other face. 
Trikotna, filmsko obložena tableta lososove barve z zarezo na obeh straneh in vrezano oznako “7.5” na eni ter na drugi strani.
STATEMENT OF ACTIVE SUBSTANCE(S) One film-coated tablet contains 5 mg ivabradine (equivalent to 5.39 mg ivabradine as hydrochloride) 
Ena filmsko obložena tableta vsebuje 5 mg ivabradina (kar ustreza 5,39 mg ivabradinijevega klorida).
The study demonstrated a clinically and statistically significant relative risk reduction of 18% in the rate of the primary composite endpoint of cardiovascular mortality and hospitalisation for worsening heart failure (hazard ratio : 0.82, 95%CI [0.75;0.90] - p<0.0001) apparent within 3 months of initiation of treatment. 
(razmerje tveganja: 0,82, 95 % interval zaupanja [0,75;0,90] - p<0,0001), vidnega po 3 mesecih po začetku zdravljenja.
Primary composite endpoint Components of the composite: - CV death - Hospitalisation for worsening HF 
- srčno-žilna smrt - hospitalizacija zaradi poslabšanja srčnega popuščanja
The antianginal and anti-ischaemic efficacy of ivabradine was preserved in diabetic patients (n = 457) with a similar safety profile as compared to the overall population. 
Antianginozni in antiishemični učinek ivabradina se je ohranjal pri bolnikih s sladkorno boleznijo
BATCH NUMBER Batch 
ŠTEVILKA SERIJE Številka serije:
If heart rate increases persistently above 60 beats per minute at rest, the dose can be up titrated to the next upper dose in patients receiving 2.5 mg twice daily or 5 mg twice daily. 
Če se srčna frekvenca med mirovanjem vztrajno povečuje nad 60 utripov na minuto, lahko odmerek titrirate navzgor do naslednjega večjega odmerka pri bolnikih, ki jemljejo 2,5 mg dvakrat na dan ali 5 mg dvakrat na dan. Zdravljenje morate prekiniti, če srčna frekvenca ostane pod 50 utripov na minuto ali simptomi bradikardije vztrajajo (glejte poglavje 4.4).
ibutilide, amiodarone). 
Ivabradin je
Metabolism and nutrition disorders 
Presnovne in prehranske motnje občasni hiperurikemija
and 45%), ivabradine did not have any deleterious influence on LVEF. 
Poleg tega ivabradin ni imel klinično signifikantnega učinka na farmakokinetiko simvastatina,
Stroke 
Odmerjanje
mefloquine, halofantrine, pentamidine, cisapride, intravenous erythromycin). 
ziprazidon, sertindol) - zdravila proti malariji (na primer meflokin ali halofantrin) - eritromicin v žilo (antibiotik) - pentamidin (zdravilo proti parazitom) - cisaprid (proti gastroezofagealnemu refluksu)
Special population 
Posebne skupine bolnikov Starejši ljudje
This summary was last updated in 11-2011. 
Povzetek je bil nazadnje posodobljen 11-2011.
It should not be poured or pumped directly into the mouth. 
Raztopina se ne sme vliti ali načrpati neposredno v usta.
It is available as tablets (5 mg, 10 mg, 15 mg and 20 mg). 
Na voljo je v obliki tablet (5 mg, 10 mg, 15 mg in 20 mg).
Axura should be given once a day, at the same time every day. 
Zdravilo Axura se daje enkrat dnevno, vsak dan ob istem času.
If the solution is used, the dose should first be pumped onto a spoon or into a glass of water. 
Če se uporablja raztopina, je treba odmerek najprej načrpati na žlico ali v kozarec vode.
The European Commission granted a marketing authorisation valid throughout the European Union for Axura on 17 May 2002. 
Evropska komisija je dovoljenje za promet z zdravilom Axura, veljavno po vsej Evropski uniji, odobrila dne 17. maja 2002.
The full EPAR for Axura can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Axura je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Alzheimer's disease is a type of dementia (a brain disorder) that gradually affects memory, intellectual ability and behaviour. 
Alzheimerjeva bolezen je vrsta demence (možganske bolezni), ki postopoma prizadene spomin, intelektualno sposobnost in vedenje.
To prevent side effects, the dose of Axura is gradually increased over the first three weeks of treatment: during the first week, the dose is 5 mg; in the second week, it is 10 mg; and during the third week, it is 15 mg. From week four onwards, the recommended maintenance dose is 20 mg once a day. 
Da se preprečijo neželeni učinki, se odmerek zdravila Axura v prvih treh tednih zdravljenja postopoma povečuje: prvi teden je odmerek 5 mg; drugi teden 10 mg, tretji teden pa 15 mg. Od četrtega tedna naprej je priporočeni vzdrževalni odmerek 20 mg enkrat dnevno.
In addition, overstimulation of the NMDA receptors can result in cell damage or death. 
Poleg tega lahko prekomerna stimulacija receptorjev NMDA povzroči poškodbo ali odmiranje celic.
The first study involved 252 patients with moderately severe to severe disease, while the other two involved a total of 873 patients with mild to moderate disease. 
Prva študija je vključevala 252 bolnikov z zmerno hudo do hudo boleznijo, drugi dve pa skupno 873 bolnikov z blago do zmerno boleznijo.
The main measures of effectiveness were the change in symptoms in three main areas: functional (the degree of disability), cognitive (the ability to think, learn and remember) and global (a combination of several areas including general function, cognitive symptoms, behaviour and the ability to carry out everyday activities). 
Glavno merilo učinkovitosti je bila sprememba simptomov na treh glavnih področjih: funkcionalnem (stopnja invalidnosti), kognitivnem (sposobnost mišljenja, učenja in pomnjenja) in globalnem (kombinacija več področij, vključno s splošno funkcijo, kognitivnimi simptomi, vedenjem in sposobnostjo izvajanja vsakodnevnih dejavnosti).
For more information about treatment with Axura, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Axura preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte s svojim zdravnikom ali farmacevtom.
Other information about Axura 
Druge informacije o zdravilu Axura
This is a summary of the European public assessment report (EPAR) for Axura. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Axura.
The most common side effects with Axura (seen in between 1 and 10 patients in 100) are somnolence (sleepiness), dizziness, hypertension (high blood pressure), dyspnoea (difficulty breathing), constipation, headache and drug hypersensitivity (allergy to the medicine). 
Najpogostejši neželeni učinki zdravila Axura (opaženi pri 1 do 10 bolnikih izmed 100) so somnolenca (zaspanost), omotica, hipertenzija (visok krvni tlak), dispneja (oteženo dihanje), zaprtje, glavobol in preobčutljivost (alergija na zdravilo).
However, when these results were considered along with those of the three additional studies, it was noted that the effect of Axura was smaller in patients with mild disease. 
Vendar pa je bilo s primerjavo teh rezultatov z rezultati treh dodatnih študij ugotovljeno, da je bil učinek zdravila Axura manjši pri bolnikih z blago boleznijo.
Memantine works by blocking special types of receptor called NMDA receptors, to which the neurotransmitter glutamate normally attaches. 
Memantin deluje tako, da zavira posebno vrsto receptorjev, imenovanih receptorji NMDA, na katere se živčni prenašalec glutamat navadno veže.
Axura was more effective than placebo at controlling the symptoms of Alzheimer's disease. 
Zdravilo Axura je bilo pri nadzorovanju simptomov Alzheimerjeve bolezni učinkovitejše od placeba.
The tolerance and dose should be assessed within 3 months after starting treatment, and from then on the benefits of continuing treatment with Axura should be reassessed on a regular basis. 
Prenašanje in odmerek zdravila je treba oceniti v 3 mesecih od začetka zdravljenja, od takrat naprej pa je treba koristi zdravljenja z zdravilom Axura ponovno ocenjevati v rednih intervalih.
Axura has been studied in three main studies including a total of 1,125 patients with Alzheimer's disease, some of whom had taken other medicines for their disease in the past. 
Zdravilo Axura so proučevali v treh glavnih študijah, ki so vključevale skupno 1 125 bolnikov z Alzheimerjevo boleznijo, pri čemer so nekateri izmed njih v preteklosti prejemali druga zdravila za zdravljenje te bolezni.
What benefit has Axura shown during the studies? 
Kakšne koristi je zdravilo Axura izkazalo med študijami?
Axura was compared with placebo (a dummy treatment) over 24 to 28 weeks. 
Zdravilo Axura so primerjali s placebom (zdravilom brez zdravilne učinkovine) v obdobju 24 do 28 tednov.
Axura is used to treat patients with moderate to severe Alzheimer's disease. 
Zdravilo Axura se uporablja za zdravljenje bolnikov z zmerno do hudo Alzheimerjevo boleznijo.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Axura. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Axura, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Changes in the way glutamate transmits signals within the brain have been linked to the memory loss seen in Alzheimer's disease. 
Spremembe načina, kako glutamat prenaša signale v možganih, se povezujejo z izgubo spomina, kakršno opažamo pri Alzheimerjevi bolezni.
EPAR summary for the public memantine hydrochloride 
Povzetek EPAR za javnost memantinijev klorid
Treatment should only be started if a caregiver is available who will regularly monitor the use of Axura by the patient. 
Zdravljenje se sme uvesti samo, če je na voljo negovalec, ki bo redno spremljal bolnikovo jemanje zdravila Axura.
Axura must not be used in people who are hypersensitive (allergic) to memantine hydrochloride or any of the other ingredients. 
Zdravila Axura ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) memantinijev klorid ali katero koli drugo sestavino zdravila.